Antios Therapeutics Secures $25 Million Series A Financing to Advance ATI-2173 for Hepatitis B and D

VCBeat (WeChat ID: vcbeat) has learned that on November 27, 2018 (U.S. local time), Antios Therapeutics (“Antios”), a biopharmaceutical company based in Georgia, announced the closing of a $25 million Series A financing round. The newly raised capital will be used to support the development of its lead oral drug candidate, ATI-2173, which is primarily indicated for the treatment of patients infected with hepatitis B virus (HBV) and potentially hepatitis D virus (HDV).

This round of financing was oversubscribed by two renowned international investment firms, Lumira Ventures and Domain Associates, with additional support from CAM Capital, Delos Capital, Quantum Vista Capital, Fonds de solidarité FTQ, and the Georgia Research Alliance Venture Fund.

Image source: Antios official website

Antios is an early-stage biopharmaceutical company focused on developing novel antiviral therapies to address unmet medical needs. The company’s primary drug candidate is a product targeting chronic hepatitis B virus (HBV) infection, a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma that affects over 250 million people worldwide.

Antios’s founding team comprises former senior executives from Pharmasset (acquired by Gilead Sciences) and Idenix (acquired by Merck). They bring decades of experience in the successful discovery, development, and commercialization of transformative therapies and technologies for treating viral infections.

“The next frontier in virology is curing hepatitis B, which is also the goal Antios is pursuing.” Dr. Abel De La Rosa, Co-Founder and CEO of Antios, stated, “The financial support provided by our investors, along with their experience and technical expertise in clinical development and infectious diseases, will significantly accelerate the development of ATI-2173.”

Following this round of financing, Dr. Beni Rovinski (Lumira Ventures), Nicole Vitullo (Domain Associates), Scott Morenstein (CAM Capital), Henry Chen (Delos Capital), and Dr. Abel De La Rosa joined the Board of Directors of Antios.

Headquartered in Atlanta, Georgia, Antios Therapeutics is an early-stage biopharmaceutical company dedicated to developing innovative therapies for viral diseases. Under the leadership of Dr. Abel De La Rosa, Co-founder and Chief Executive Officer, and Dr. Douglas Mayers, Co-founder and Chief Medical Officer, the company is currently focused on developing its lead oral drug candidate for the treatment of HBV infection.

Lumira Ventures, headquartered in Ontario, Canada, is a venture capital firm that invests in life sciences and biotechnology companies across North America. Over the past five years, Lumira Ventures and its partners have cumulatively helped entrepreneurs establish more than 50 companies.

Domain Associates, founded in 1985 and headquartered in California, USA, is a venture capital firm focused on life sciences, managing over $2 billion in assets. Domain Associates primarily concentrates on early-stage venture capital, late-stage venture capital, and private equity investments.